Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: A two-year, multicenter, multiple-dose, placebo-controlled study

被引:102
作者
Underwood, LE
Attie, KM
Baptista, J
机构
[1] Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC 27599 USA
[2] Genentech Inc, San Francisco, CA 94080 USA
关键词
D O I
10.1210/jc.2003-030204
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
GH replacement therapy has been shown to improve abnormalities in body composition, bone mineral density (BMD), lipid profile, and other changes resulting from GH deficiency (GHD) in adults. There is, however, need to determine appropriate dosing in young adults who were treated for GHD as children, to bridge the interval between childhood (in which relatively high doses are used) and older adulthood (in which only lower doses are tolerated). This multicenter, randomized, double-blind, placebo-controlled study compares the safety and efficacy of two doses of GH (25 and 12.5 mug/kg.d) with placebo, maintained for 2 yr, in adults with GHD who were treated as children and were off GH for at least 1 yr (mean, 5.6 yr). The 64 treated subjects were less than 35 yr of age ( mean, 23.8 yr) and had maximum serum GH responses, on retesting less than 5 mug/liter (mean, 0.7 mug/liter). At baseline, 22% had spine BMD below -2 SD, 59% were overweight or obese, and 45% had serum total cholesterol more than 200 mg/dl. A significant dose response was seen for percent increase in spine BMD at 24 months (mean of 1.3%, 3.3%, and 5.2% in the placebo, 12.5-, and 25-mug/kg.d groups, respectively, P = 0.018). Both GH-treated groups had similar changes in body composition at 6 months (decreased fat mass, increased lean mass); however, some gains were subsequently lost in the lower dose group. A significant decrease in low-density lipoprotein cholesterol was seen only in the higher GH dose group. Significant changes were not observed in quality of life and echocardiographic measures. The groups were similar with regard to adverse events and laboratory measurements, except for a higher incidence of edema in the GH-treated groups. We conclude that this dose-response study confirms the benefits of GH-replacement therapy in GHD adults and indicates that, to achieve treatment goals in younger adults, higher doses may be needed than those generally used in older adults.
引用
收藏
页码:5273 / 5280
页数:8
相关论文
共 43 条
[21]   Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects [J].
Hilding, A ;
Hall, K ;
Wivall-Helleryd, IL ;
Sääf, M ;
Mellin, AL ;
Thorén, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (06) :2013-2019
[22]  
Hollander M., 1973, Nonparametric Statistical Methods
[23]   A switch from oral (2 mg/day) to transdermal (50 μg/day) 17β-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency [J].
Janssen, YJH ;
Helmerhorst, F ;
Frölich, M ;
Roelfsema, F .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (01) :464-467
[24]   Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency [J].
Johannsson, G ;
Rosen, T ;
Bosaeus, I ;
Sjostrom, L ;
Bengtsson, BA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (08) :2865-2873
[25]  
JORGENSEN JOL, 1989, LANCET, V1, P1221
[26]   3 YEARS OF GROWTH-HORMONE TREATMENT IN GROWTH HORMONE-DEFICIENT ADULTS - NEAR NORMALIZATION OF BODY-COMPOSITION AND PHYSICAL PERFORMANCE [J].
JORGENSEN, JOL ;
THUESEN, L ;
MULLER, J ;
OVESEN, P ;
SKAKKEBAEK, NE ;
CHRISTIANSEN, JS .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1994, 130 (03) :224-228
[27]   SERUM INSULIN-LIKE GROWTH FACTOR-I IN 1030 HEALTHY-CHILDREN, ADOLESCENTS, AND ADULTS - RELATION TO AGE, SEX, STAGE OF PUBERTY, TESTICULAR SIZE, AND BODY-MASS INDEX [J].
JUUL, A ;
BANG, P ;
HERTEL, NT ;
MAIN, K ;
DALGAARD, P ;
JORGENSEN, K ;
MULLER, J ;
HALL, K ;
SKAKKEBAEK, NE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (03) :744-752
[28]   Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset:: A comparative, prospective study [J].
Koranyi, J ;
Svensson, J ;
Götherström, G ;
Sunnerhagen, KS ;
Bengtsson, BÅ ;
Johannsson, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (10) :4693-4699
[29]   High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: A randomized, multicenter trial [J].
Mauras, N ;
Attie, KM ;
Reiter, EO ;
Saenger, P ;
Baptista, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3653-3660
[30]   PSYCHOLOGICAL WELL-BEING BEFORE AND AFTER GROWTH-HORMONE TREATMENT IN ADULTS WITH GROWTH-HORMONE DEFICIENCY [J].
MCGAULEY, GA ;
CUNEO, RC ;
SALOMON, F ;
SONKSEN, PH .
HORMONE RESEARCH, 1990, 33 :52-54